TG THERAPEUTICS, INC. Proceeds from Notes Payable
TG THERAPEUTICS, INC. (TGTX) reported Proceeds from Notes Payable of $1.51 million for the 122-month period ending 2011-09-30, per its 10-Q filed 2011-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2011-11-14
- TG THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2011-09-30 was $0.00.
- TG THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2010-09-30 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 119 month | Proceeds from Notes Payable 122 month |
|---|---|---|---|---|---|
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $0.00 10-Q · filed 2011-11-14 | $1.51M 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $0.00 10-Q/A · filed 2011-09-14 | $1.51M 10-Q/A · filed 2011-09-14 | |||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $0.00 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | $0.00 10-Q/A · filed 2011-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |